Anti-Coagulants - Bosnia and Herzegovina

Bosnia and Herzegovina

The revenue in the Anti-Coagulants market of Bosnia and Herzegovina is estimated to reach US$4.72m by the year 2024.
It is projected to exhibit an annual growth rate (CAGR 2024-2028) of 7.66%, leading to a market volume of US$6.34m by 2028.
When compared globally, United States is expected to generate the highest revenue of US$16,740.00m in 2024.
Bosnia and Herzegovina is experiencing a growing demand for anti-coagulants due to an aging population and an increased prevalence of cardiovascular diseases.

Key regions: Germany, South Korea, France, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Bosnia and Herzegovina is developing at a steady pace with a focus on improving patient outcomes and reducing the risk of complications associated with blood clots.

Customer preferences: Patients in Bosnia and Herzegovina are increasingly aware of the benefits of Anti-Coagulants in preventing blood clots and reducing the risk of stroke. As a result, they are more likely to seek treatment for conditions that require Anti-Coagulants, such as atrial fibrillation and deep vein thrombosis.

Trends in the market: The Anti-Coagulants market in Bosnia and Herzegovina is witnessing a shift towards newer oral Anti-Coagulants, which are more effective and safer than traditional Anti-Coagulants such as warfarin. This trend is driven by the increasing availability of these drugs and the growing body of clinical evidence supporting their use.

Local special circumstances: Bosnia and Herzegovina has a relatively small Anti-Coagulants market compared to other European countries, which presents opportunities for growth. However, the market is also highly fragmented and competitive, with many local and international players vying for market share.

Underlying macroeconomic factors: The Anti-Coagulants market in Bosnia and Herzegovina is influenced by a range of macroeconomic factors, including healthcare spending, regulatory policies, and demographic trends. The government's efforts to improve healthcare infrastructure and increase access to medicines are likely to drive growth in the Anti-Coagulants market. Additionally, the aging population and the increasing prevalence of chronic diseases are expected to increase demand for Anti-Coagulants in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.